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BES SES OR 95% CI
Deﬁnite stent thrombosis
0-3 years 17 (1.4%) 12 (1.0%) 1.45 (0.69-3.13)
0-1 year 10 (0.8%) 3 (0.2%) 3.41 (1.04-15.3)
1-2 years 6 (0.5%) 3 (0.2%) 2.16 (0.57-10.3)
2-3 years 1 (0.1%) 6 (0.5%) 0.17 (0.01-0.98)
Very late stent thrombosis 7 (0.6%) 9 (0.7%) 0.81 (0.29-2.19)
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Background: There is limited head-to-head data on long-term safety and efﬁcacy
outcomes for everolimus-eluting stent (EES) and sirolimus-eluting stent (SES).
Methods: In the SORT OUT (Scandinavian Organization for Randomized Trials with
Clinical Outcome) IV trial we prospectively randomized 2,774 patients. The SORT
OUT IV trial demonstrated non-inferiority of the EES to the SES at 9 months. Follow-
up through 5 years was complete in 2,770 (99.9%)). The 5-year pre-speciﬁed endpoint
was a composite of safety and efﬁcacy (major adverse cardiac event (MACE): cardiac
death, myocardial infarction, target vessel revascularization and deﬁnite stent
thrombosis).
Results: At 4-year EES remained non-inferior to SES for the composite primary end
point which occurred in 11.8% in the EES group and in 14.7% in the SES group
(hazard ratio (HR) 0.80, 95% conﬁdence interval (CI) 0.65-0.98). Cardiac death 3.8%
vs. 3.9% (HR 0.98, 95% CI 0.67-1.43) did not differ between the two groups, whereas
target lesion revascularization (EES 4.2% vs. SES 6.2%, (HR 0.68, 95% CI 0.49-0.95)
and myocardial infarction (EES 2.9% vs. SES 4.3%, (HR 0.67, 95% CI 0.45-1.00).
Deﬁnite stent thrombosis were lower in the EES group (0.3%) compared to the SES
group (2.0%) (HR¼0.15, 95% CI 0.05-0.45) which largely was attributable to a lower
risk of very late deﬁnite stent thrombosis: 0.1% versus 1.3% (HR¼0.11, 95% CI 0.03-
0.47). The 5-year results will be available for presentation at the TCT meeting 2014.
Conclusions: At 4-year follow-up, MACE rate was signiﬁcantly lower in EES treated
patients compared to SES. The 5-year results will be available for presentation at the
TCT meeting 2014.
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Background: Drug-eluting stents with biodegradable polymers have been developed
to address the risk of very late adverse events such as stent thrombosis. The purpose of
this analysis was to compare incidence of stent thrombosis in an all-comers percu-
taneous coronary intervention (PCI) cohort treated with the biodegradable polymer-
coated biolimus-eluting stent (Nobori; BES) or the durable polymer-coated
everolimus-eluting stent (Xience or Promus; EES).
Methods: The COMPARE II study is an open-label, prospective, randomized, non-
inferiority, all-comer trial undertaken at 12 sites across Europe currently at 3-year
follow-up. Patients were randomly allocated (2:1) to receive either a BES or EES.
Stent thrombosis was deﬁned according to the Academic Research Consortium.
Results: Of the 2707 study patients (4025 lesions), 2683 (99.1 %) completed 3 years








All Stent Thrombosis 0.8% (7) 1.2% (21) 1.52 [0.65-3.57] 0.33
Early Stent Thrombosis 0.3% (3) 0.6% (11) 1.86 [0.52-6.66] 0.33





0.3% (3) 0.5% (8) 1.36 [0.36-5.09] 0.65
Deﬁnite or Probable Stent Thrombosis
All Stent Thrombosis 1.4% (13) 1.3% (23) 0.90 [0.46-1.77] 0.76
Early Stent Thrombosis 0.8% (7) 0.6% (11) 0.80 [0.31-2.05] 0.64
Late Stent Thrombosis 0.2% (2) 0.2% (3) 0.76 [0.13-4.55] 0.77
Very Late Stent
Thrombosis
0.4% (4) 0.5% (9) 1.14 [0.35-3.70] 0.82
JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteConclusions: At 3-year follow-up the biodegradable polymer-coated BES has similar
stent thrombosis rates as the durable polymer-coated EES without observing any
tendency for reduction in frequency of this event beyond 1 year. In comparison to
second-generation durable polymer coated DES, these results challenge the concept of
biodegradable polymers.
TCT-643
Very Late Stent Thrombosis after Revascularization with Biolimus-Eluting
Biodegradable Polymer-Coated Nobori Stent versus Durable Polymer-Coated
Sirolimus-Eluting Stents from the SORT OUT V Trial
Evald H. Christiansen1, Lisette Okkels Jensen2, Per Thayssen3, Hans-Henrik Tilsted4,
Lars Krusell5, Anne Kaltoft6, Michael Maeng7, Jan Ravkilde8, Jens F. Lassen9
1Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus N, Denmark,
2Odense University Hospital, Odense, Denmark, 3N/A, Odense, Denmark, 4Aarhus
University Hospital, Aalborg, Aalborg, Denmark, 5Aarhus University Hospital,
Skejby, Aarhus, Denmark, 6Dept. of Cardiology, Aarhus Universityhospital, Skejby,
Denmark, Aarhus, Denmark, 7Aarhus University Hospital, Aarhus, Denmark,
8Aalborg University Hospital, Aalborg, Denmark, 9Department of Cardiology,
Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark
Background: There is limited head-to-head data on late stent-related outcomes for
biolimus-eluting biodegradable (BES) polymer-coated Nobori stent and durable
polymer-coated sirolimus-eluting stent (SES).
Methods: In the SORT OUT (Scandinavian Organization for Randomized Trials with
Clinical Outcome) V trial we prospectively randomized 2468 patients. The SORT
OUT V trial did not demonstrate non-inferiority of the BES to the SES at 9 months.
Follow-up through 3 years is complete in 2467 (99.96%). The 3-year pre-speciﬁed
endpoint was a composite of safety and efﬁcacy (MACE: cardiac death, myocardial
infarction and target vessel revascularization and deﬁnite stent thrombosis) and the
safety endpoint of interest was deﬁnite stent thrombosis.
Results: At 3-year MACE rate did not differ signiﬁcantly between the two groups:
BES group (10.1%) compared to the SES group (11.2%) (hazard ratio (OR) 0.90, 95%
conﬁdence interval (CI) 0.69-1.16). Deﬁnite stent thrombosis occurred within 3 years
in 30 patients (1.2%). Overall rate of deﬁnite stent thrombosis did not differ signiﬁcant
between BES or SES treated patients (1.4% versus 1.0%, (OR¼1.33, 95% CI
0.64-2.81)).Conclusions: At 3-year follow-up the Nobori stent with a biodegradable polymer was
not associated with a lower risk of MACE or deﬁnite stent thrombosis compared to the
Cypher stent with a durable polymer. However, the risk of stent thrombosis was time-
dependent. In the ﬁrst year the risk was higher in the Nobori group. In the period from
2 to 3 year after implantation the risk was lower in the Nobori group
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Background: Drug-eluting stents with biodegradable polymers have been developed
to reduce the risk of very late adverse events such as stent thrombosis. Recent studies
have indicated similar results with regard to safety outcomes for the biodegradable
polymer-coated biolimus-eluting stent (Nobori; BES) compared to the durable
polymer-coated everolimus-eluting stent (Xience or Promus; EES) at 1 year.
However, these trials were not powered to detect differences in low-frequency events
such as stent thrombosis.
Methods: The all-comers COMPARE II and NEXT clinical trials randomly assigned
5942 patients to BES or EES and is at present the largest pooled analysis of BES in
all-comers requiring percutaneous coronary intervention (PCI). Here we conducted a
patient level analysis at 1 year to assess rates of stent thrombosis deﬁned according to
the Academic Research Consortium.
Results: The pooled unadjusted 1-year stent thrombosis rates of the 5942 study pa-
tients (8094 lesions) are tabulated. Covariate adjusted analyses accounting for baselinents - Drug-Eluting: Stent Thrombosis B187
